Displaying drugs 1351 - 1375 of 2778 in total
Name | Weight | Structure | Description | Categories |
---|---|---|---|---|
Leuprolide | 1209.3983 C59H84N16O12 | A peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty. | Gonadotropin-releasing hormone agonist | |
Leucovorin | 473.446 C20H23N7O7 | A folate analog used to treat the toxic effects of methotrexate and other folate antagonists, to treat megaloblastic anemia, and to provide palliative treatment of colorectal cancer. | Detoxifying Agents for Antineoplastic Treatment | |
Letrozole | 285.3027 C17H11N5 | An aromatase inhibitor used to treat breast cancer in postmenopausal women. | Antineoplastic Agents / Aromatase Inhibitors / Nitriles / Triazoles | |
Letermovir | 572.561 C29H28F4N4O4 | An antiviral medication used for prophylaxis in adult transplant recipients at risk of cytomegalovirus (CMV) infection and disease. | Antiviral Agents / Cytomegalovirus DNA Terminase Complex Inhibitor / Poly(ADP-ribose) Polymerase Inhibitors | |
Lesinurad | 404.28 C17H14BrN3O2S | A uric acid 1 transporter inhibitor typically used in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout in patients with inadequate control of uric acid levels with xanthine oxidase inhibitor monotherapy. | Preparations Increasing Uric Acid Excretion | |
Lercanidipine | 611.7272 C36H41N3O6 | A calcium channel blocker for the management of hypertension. | ACE Inhibitors and Calcium Channel Blockers / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Dihydropyridine Derivatives | |
Lenvatinib | 426.86 C21H19ClN4O4 | A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. | Protein Kinase Inhibitors | |
Leniolisib | 450.466 C21H25F3N6O2 | A phosphoinositide 3-kinase-delta inhibitor that is used to treat activated phosphoinositide 3-kinase delta syndrome. | BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Kinase Inhibitor / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein substrates | |
Lenalidomide | 259.2606 C13H13N3O3 | A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome. | Angiogenesis Inhibitors / Immunologic Factors / Phthalimides / Piperidones / Thalidomide Analog | |
Lenacapavir | 968.28 C39H32ClF10N7O5S2 | A first-in-class capsid inhibitor being investigated for use in HIV-1 treatment. | Anti-HIV Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Heterocyclic Compounds, Fused-Ring / Human Immunodeficiency Virus 1 Capsid Inhibitor / P-glycoprotein substrates / Pyrazoles / UGT1A1 Substrates | |
Lemborexant | 410.425 C22H20F2N4O2 | A dual orexin antagonist indicated for the treatment of sleep-onset and/or sleep maintenance insomnia. | Orexin Receptor Antagonists | |
Leflunomide | 270.2073 C12H9F3N2O2 | A pyrimidine synthesis inhibitor indicated to treat rheumatoid arthritis. | Selective Immunosuppressants | |
Lefamulin | 507.73 C28H45NO5S | A pleuromutilin antibacterial used to treat community-acquired bacterial pneumonia (CABP). | Anti-Bacterial Agents | |
Ledipasvir | 888.9999 C49H54F2N8O6 | A direct-acting antiviral agent used to treat specific hepatitis C virus (HCV) infections in combination with other antiviral agents. | Antivirals for treatment of HCV infections | |
Laurocapram | 281.484 C18H35NO | Not Annotated | Not Annotated | |
Lauric acid | 200.3178 C12H24O2 | Lauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression. Lauric acid is a solid at room temperature but melts easily... | Fatty Acids / Lipids | |
Latanoprostene bunod | 507.624 C27H41NO8 | A prostaglandin analog used to reduce ocular hypertension or treat open-angle glaucoma. | Prostaglandins, Synthetic | |
Latanoprost | 432.5928 C26H40O5 | An isopropyl ester prodrug used to treat increased intraocular pressure. | Antihypertensive Agents / Ophthalmic Solutions / Prostaglandins F, Synthetic / Prostaglandins, Synthetic | |
Latamoxef | 520.473 C20H20N6O9S | Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections,... | Anti-Bacterial Agents / Third-Generation Cephalosporins | |
Lasofoxifene | 413.5512 C28H31NO2 | Investigated for use/treatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures, as well as address other postmenopausal conditions, including reduction in risk of breast cancer... | Selective Estrogen Receptor Modulators | |
Lasmiditan | 377.367 C19H18F3N3O2 | An oral 5HT1F agonist used for the acute treatment of migraine headache with or without aura. | Amides / Analgesics / Antidepressive Agents / Antimigraine Preparations / BCRP/ABCG2 Inhibitors / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Nervous System / Neurotransmitter Agents / OCT1 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin (5-HT) 1F Receptor Agonists / Serotonin Agents | |
Larotrectinib | 428.444 C21H22F2N6O2 | A kinase inhibitor used to treat solid tumors with neurotrophic receptor tyrosine kinase gene fusion, are metastatic, high risk for surgery, or have no alternative treatments. | Protein Kinase Inhibitors | |
Laropiprant | 435.89 C21H19ClFNO4S | Laropiprant is an ingredient in the EMA-withdrawn product Pelzont. | Heterocyclic Compounds, Fused-Ring | |
Lapyrium | 363.521 C21H35N2O3 | Used as a surfactant, antistatic agent, and biocide in cosmetic products . | Pyridines | |
Lapatinib | 581.058 C29H26ClFN4O4S | An antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-positive breast cancer in patients who received prior chemotherapeutic treatments. | Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors / Protein Kinase Inhibitors |
Displaying drugs 1351 - 1375 of 2778 in total